# Effect of Preoperative Iron Isomaltoside 1000 Administration on Hemoglobin Concentration in Patients Undergoing Transcatheter Aortic Valve Implantation

Study · id `cardio:ct-nct04346004` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04346004](<https://clinicaltrials.gov/study/NCT04346004>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04346004

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 214 participants.

## Technical summary

Registry record NCT04346004. Randomized; quadruple masking; primary purpose prevention. Start 2020-04-27 (actual); primary completion 2023-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 214 participants (planned count; ClinicalTrials.gov record NCT04346004, source copy `cardio:ctgov-nct04346004-2020-04-30`, retrieved 2026-10-26)
- Started: 2020-04-27 (actual) (ClinicalTrials.gov record NCT04346004, source copy `cardio:ctgov-nct04346004-2020-04-30`, retrieved 2026-10-26)
- Primary completion: 2023-03 (anticipated) (ClinicalTrials.gov record NCT04346004, source copy `cardio:ctgov-nct04346004-2020-04-30`, retrieved 2026-10-26)
- Completion: 2023-03 (anticipated) (ClinicalTrials.gov record NCT04346004, source copy `cardio:ctgov-nct04346004-2020-04-30`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04346004, source copy `cardio:ctgov-nct04346004-2020-04-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04346004-2020-04-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Preoperative Iron Isomaltoside 1000 Administration on Hemoglobin Concentration in Patients Undergoing Transcatheter Aortic Valve Implantation
- Condition: Aortic Stenosis (Treated With TAVI)
- Intervention (Drug): Normal saline
- Intervention (Drug): Iron isomaltoside
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: 02d4478e1d52f9bfbcf511e61ef83cddd44ef37251324b6040516c569d37fc7c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
